See more : Sai Capital Ltd. (SAICAPI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of HOOKIPA Pharma Inc. (HOOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOOKIPA Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aedas Homes, S.A. (AEDAS.MC) Income Statement Analysis – Financial Results
- Rainbow Digital Commercial Co., Ltd. (002419.SZ) Income Statement Analysis – Financial Results
- TILT Holdings Inc. (TLLTF) Income Statement Analysis – Financial Results
- Savannah Energy PLC (SVNNF) Income Statement Analysis – Financial Results
- Bandwidth Inc. (BAND) Income Statement Analysis – Financial Results
HOOKIPA Pharma Inc. (HOOK)
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.13M | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 3.55M | 3.60M | 4.64M | 53.13M | 46.31M | 21.97M | 398.00K |
| Gross Profit | 16.58M | 10.65M | 13.81M | -33.55M | -34.37M | -14.34M | -398.00K |
| Gross Profit Ratio | 82.35% | 74.72% | 74.85% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 86.42M | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | -392.00K | -2.84M | 3.07M | 601.00K | 133.00K | -25.00K |
| Operating Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Cost & Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Interest Income | 5.29M | 8.24M | 27.00K | 9.20M | 1.59M | 0.00 | 0.00 |
| Interest Expense | 317.00K | 687.00K | 898.00K | 786.00K | 877.00K | 778.00K | 606.00K |
| Depreciation & Amortization | 3.55M | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -77.34M | -60.40M | -70.13M | -39.15M | -39.09M | -14.80M | -13.76M |
| EBITDA Ratio | -384.24% | -513.40% | -442.73% | -272.08% | -427.78% | -193.93% | 0.00% |
| Operating Income | -97.69M | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -485.34% | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 16.48M | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -81.21M | -64.92M | -75.67M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -403.46% | -455.58% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 368.00K | 230.00K | 1.00K | -10.28M | -8.89M | 24.00K | 4.00K |
| Net Income | -81.58M | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| EPS Diluted | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| Weighted Avg Shares Out | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
Best Penny Stocks To Buy This Week? 4 To Watch Now
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
HOOKIPA Announces Executive Leadership Change
Source: https://incomestatements.info
Category: Stock Reports